In recent years, ICIs targeting programmed death 1 (PD-1), PD-L1, and cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) as the first-line treatment for driver-gene-negative advanced NSCLC are a hot research territory. The gene discussed is CD274; the disease is non-small cell lung carcinoma.